Remove Clinical Trials Remove Data Remove Media Remove Programs
article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

article thumbnail

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: Entheon Biomedical Announces EEG Patent Application & Provides Research Update

Cannabis Law Report

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

article thumbnail

Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer

Cannabis Law Report

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Media: Liz Melone.

article thumbnail

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Cannabis Law Report

Anderson will be responsible for Anebulo’s global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders.

article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. What if most of it is not based on the level of scientific certainty that cannabis marketing teams and media outlets would have us believe? The cannabis research problem.